Andrew N. Schiff M.d.

Biography

Dr. Andrew N. Schiff, also known as Drew, M.D. has been Managing Director at Aisling Capital LLC since 1999 and has been its Managing Partner since 2002. He also serves as a Co-President at Aisling Capital LLC. Dr. Schiff joined Aisling Capital in September 1999. He serves as Managing Partner and Managing Director at Aisling Capital III, L.P., Perseus-Soros Biopharmaceutical Fund, L.P. and Aisling Capital II, L.P. Since June 1990, he has practiced internal medicine for six years at The New York Presbyterian Hospital, where Dr. Schiff maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff serves as a Director of ARMGO Pharma, Inc., PowerVision, Dynova Laboratories, LLC (alternate name, Dynova Laboratories, Inc.) and Henry Street Settlement. He has been a Director of Sirion Holdings, Inc. since April 2007 and Planet Biopharmaceuticals, Inc. since November 2007. He serves as Member of Advisory Board at Christie's Inc. He serves as a Member of American Advisory Board Members at Christie's International SA. Dr. Schiff has been an Observer on the Board of Zavante Therapeutics, Inc. since March 30, 2016. He has been an Independent Director at Aclaris Therapeutics, Inc. since August 9, 2017. Dr. Schiff has been a Director of SkinMedica, Inc. since February 2004. Dr. Schiff serves as a director of Sirion Therapeutics, Inc. and Visiting Nurse Service of New York, Inc. He served as a Director of Agile Therapeutics, Inc., since July 19, 2012 until February 24, 2016. Dr. Schiff served as a Director of Barrier Therapeutics, Inc. from May 2002 to July 14, 2005. He served as a Director of Gilead Colorado, Inc. from December 2001 to March 11, 2005. Dr. Schiff served as a Director of ZELTIQ Aesthetics, Inc. since July 2010 until April 28, 2017. He served as a Director of Zanett Inc. from October 2000 to September 2004. Dr. Schiff served as Director of TransEnterix, Inc. since October 2009. He served as a Director of Bioenvision, Inc. from May 2002 to July 13, 2007. Dr. Schiff served as a Director at Cardiokine, Inc., Myogen, ArgiNOx Pharmaceuticals, Inc., and Cempra Pharmaceuticals, Inc. He served as a Director of Adams Respiratory Therapeutics, Inc. from 2001 to February 2007 and Miramar Labs, Inc. Dr. Schiff served as a Board Observer of Quintiles and Cempra, Inc. He received an M.D. from Cornell University Medical College and an M.B.A. from Columbia University. Dr. Schiff also received a B.S. degree in Neuroscience, with honors, from the Brown University. Dr. Andrew N. Schiff, also known as Drew, M.D. has been Managing Director at Aisling Capital LLC since 1999 and has been its Managing Partner since 2002. He also serves as a Co-President at Aisling Capital LLC. Dr. Schiff joined Aisling Capital in September 1999. He serves as Managing Partner and Managing Director at Aisling Capital III, L.P., Perseus-Soros Biopharmaceutical Fund, L.P. and Aisling Capital II, L.P. Since June 1990, he has practiced internal medicine for six years at The New York Presbyterian Hospital, where Dr. Schiff maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff serves as a Director of ARMGO Pharma, Inc., PowerVision, Dynova Laboratories, LLC (alternate name, Dynova Laboratories, Inc.) and Henry Street Settlement. He has been a Director of Sirion Holdings, Inc. since April 2007 and Planet Biopharmaceuticals, Inc. since November 2007. He serves as Member of Advisory Board at Christie's Inc. He serves as a Member of American Advisory Board Members at Christie's International SA. Dr. Schiff has been an Observer on the Board of Zavante Therapeutics, Inc. since March 30, 2016. He has been an Independent Director at Aclaris Therapeutics, Inc. since August 9, 2017. Dr. Schiff has been a Director of SkinMedica, Inc. since February 2004. Dr. Schiff serves as a director of Sirion Therapeutics, Inc. and Visiting Nurse Service of New York, Inc. He served as a Director of Agile Therapeutics, Inc., since July 19, 2012 until February 24, 2016. Dr. Schiff served as a Director of Barrier Therapeutics, Inc. from May 2002 to July 14, 2005. He served as a Director of Gilead Colorado, Inc. from December 2001 to March 11, 2005. Dr. Schiff served as a Director of ZELTIQ Aesthetics, Inc. since July 2010 until April 28, 2017. He served as a Director of Zanett Inc. from October 2000 to September 2004. Dr. Schiff served as Director of TransEnterix, Inc. since October 2009. He served as a Director of Bioenvision, Inc. from May 2002 to July 13, 2007. Dr. Schiff served as a Director at Cardiokine, Inc., Myogen, ArgiNOx Pharmaceuticals, Inc., and Cempra Pharmaceuticals, Inc. He served as a Director of Adams Respiratory Therapeutics, Inc. from 2001 to February 2007 and Miramar Labs, Inc. Dr. Schiff served as a Board Observer of Quintiles and Cempra, Inc. He received an M.D. from Cornell University Medical College and an M.B.A. from Columbia University. Dr. Schiff also received a B.S. degree in Neuroscience, with honors, from the Brown University.

Research Interest

Business & Management